Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats

International Heart Journal

Volumn 47, Issue 5, 2006, Pages 783-793

  Okada, Takuya ^a   Nagai, Makoto ^a   Taniguchi, Ikuo ^a   Kuno, Mamoru ^a   Imamoto, Satoshi ^a   Seki, Shingo ^a   Taniguchi, Masayuki ^a   Mochizuki, Seibu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aldosterone blocker; Angiotensin receptor blocker; Cardiac fibrosis; Cardiac hypertrophy; Renin angiotensin aldosterone system; Spironolactone; Valsartan

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; SPIRONOLACTONE; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MECHANISM; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART WEIGHT; HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; VASCULAR FIBROSIS;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOVASCULAR PHYSIOLOGY; HYPERTENSION, RENOVASCULAR; MALE; MYOCARDIUM; RATS; RATS, WISTAR; SPIRONOLACTONE; TETRAZOLES; VALINE; VENTRICULAR REMODELING;

EID: 33751085609     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.47.783     Document Type: Article

References (24)

1. Remme WJ. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. Cardiovasc Drugs Ther 2003; 17: 349-60. (Review)
2. Kabour A, Henegar JR, Devineni VR, Janicki JS. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res 1995; 29: 543-8.
3. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-6.
4. Fiebeler A, Schmidt F, Muller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin II-induced cardiac injury. Hypertension 2001; 37: 787-93.
5. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994; 26: 279-92. (Review)
6. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001; 1: 190-6. (Review)
7. Maggioni AP, Latini R. RAAS inhibitors in the cardiovascular continuum: what is still missing? Cardivasc Drugs Ther 2004; 18: 311-20. (Review)
8. Obayashi M, Yano M, Kohno M, et al. Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 1997; 273: 24-31.
9. Dussaillant GR, Gonzalez H, Cespedes C, Jalil JE. Regression of left ventricular hypertrophy in experimental renovascular hypertension: diastolic dysfunction depends more on myocardial collagen than it does on myocardial mass. J Hypertens 1996; 14: 1117-23.
10. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. RALES. N Engl J Med 1999; 341: 709-17.
11. Nagai M, Horikoshi K, Izumi T, et al. Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther 2004; 18: 353-62.
12. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R: Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003; 1306-9.
13. Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
15. Tanabe A, Naruse M, Hara Y, et al. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. J Hypertens 2004; 22: 1017-23.
16. Tanaka Y, Nagai M, Date T, et al. Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 2004; 27: 865-75.
17. Ito N, Isoyama S, Takahashi T, Takishima T. Coronary dilator reserve and morphological changes after relief of pressure-overload in rats. J Mol Cell Cardiol 1993; 25: 3-14.
18. Tamura T, Said S, Harris J, Lu W, Gerdes AM. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 2000; 102: 253-9.
19. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995; 91: 691-7.
20. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-7.
21. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.
22. Silverstre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998; 273: 4883-91.
23. Satoh M, Nakamura M, Saitoh H, et al. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci 2002; 102: 381-6.
24. Cheung BM, Kumana CR. Natriuretic peptides - relevance in cardiovascular disease. JAMA 1998; 280: 1983-4.